Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
$3.62
-6.9%
$3.61
$1.75
$10.00
$246.77M0.67713,667 shs1.18 million shs
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
$10.39
-9.7%
$9.07
$6.11
$19.00
$973.99M1.995,610 shs92,430 shs
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
$23.36
-5.0%
$20.03
$16.16
$26.55
$946.15M0.62195,539 shs291,513 shs
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
$6.35
-0.6%
$7.56
$4.25
$16.74
$978.47M-0.921.28 million shs1.10 million shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
-6.94%+12.95%+19.47%-26.42%+60.18%
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
-9.65%+17.07%+34.59%-11.80%-34.12%
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
-5.04%+20.47%+30.43%-7.26%+28.28%
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
-0.63%-2.53%+5.83%-41.20%+8.73%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
2.3505 of 5 stars
3.61.00.00.02.72.50.6
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
0.2627 of 5 stars
0.02.00.00.01.81.70.0
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
3.6576 of 5 stars
0.83.02.51.13.43.32.5
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
4.3007 of 5 stars
3.51.00.04.82.64.20.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
3.25
Buy$16.33351.20% Upside
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
3.00
BuyN/AN/A
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
1.50
Reduce$20.00-14.38% Downside
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
3.00
Buy$21.17233.33% Upside

Current Analyst Ratings Breakdown

Latest CRVS, WVE, GYRE, and PAHC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/9/2025
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$15.00 ➝ $17.00
5/8/2025
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$20.00 ➝ $21.00
4/29/2025
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$10.00
4/15/2025
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$20.00
4/8/2025
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$18.00
3/26/2025
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$14.00 ➝ $15.00
3/26/2025
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
3/26/2025
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$22.00 ➝ $22.00
3/11/2025
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
Noble Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform
3/5/2025
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$22.00 ➝ $22.00
2/25/2025
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$26.00
(Data available from 5/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
N/AN/AN/AN/A$0.79 per shareN/A
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
$105.76M9.21$0.21 per share50.49$0.18 per share57.72
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
$1.11B0.86$2.15 per share10.87$6.09 per share3.84
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
$108.30M9.03N/AN/A$0.40 per share15.88
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
-$27.03M-$0.98N/AN/AN/AN/A-70.71%-45.90%N/A
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
-$92.93M$0.02519.50N/A-84.57%-118.43%-71.97%N/A
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
$2.42M$0.7848.6711.120.451.75%25.35%6.21%N/A
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
-$57.51M-$0.84N/AN/AN/A-66.50%-280.57%-52.90%N/A

Latest CRVS, WVE, GYRE, and PAHC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2025Q1 2025
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
$0.03$0.03N/AN/A$28.40 million$22.06 million
5/8/2025Q1 2025
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
-$0.13-$0.13N/A-$0.13N/AN/A
5/8/2025Q1 2025
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
-$0.27-$0.29-$0.02-$0.29$11.65 million$9.18 million
5/7/2025Q3 2025
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
$0.52$0.63+$0.11$0.51$352.41 million$347.80 million
3/25/2025Q4 2024
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
-$0.12-$0.18-$0.06-$0.18N/AN/A
3/17/2025Q4 2024
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
$0.04$0.01-$0.03$0.02$23.50 million$27.87 million
3/4/2025Q4 2024
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
-$0.17$0.17+$0.34$0.17$25.60 million$83.75 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
N/AN/AN/AN/AN/A
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
N/AN/AN/AN/AN/A
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
$0.482.05%N/A61.54%N/A
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
N/AN/AN/AN/AN/A

Latest CRVS, WVE, GYRE, and PAHC Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/6/2025
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
quarterly$0.122.52%6/4/20256/4/20256/25/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
N/A
0.92
0.92
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
N/A
3.72
3.29
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
2.99
3.20
1.37
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
N/A
1.90
1.90

Institutional Ownership

CompanyInstitutional Ownership
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
46.64%
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
23.99%
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
99.34%
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
89.73%

Insider Ownership

CompanyInsider Ownership
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
28.50%
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
19.52%
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
50.07%
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
29.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
3068.17 million44.15 millionOptionable
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
4093.74 million75.27 millionNo Data
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
1,86040.50 million20.22 millionOptionable
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
240154.09 million108.14 millionOptionable

Recent News About These Companies

Wave Life Sciences Ltd. stock logo
FY2028 Earnings Estimate for WVE Issued By Wedbush
StockNews.com Downgrades Wave Life Sciences (NASDAQ:WVE) to Sell

New MarketBeat Followers Over Time

Media Sentiment Over Time

Corvus Pharmaceuticals stock logo

Corvus Pharmaceuticals NASDAQ:CRVS

$3.62 -0.27 (-6.94%)
As of 05/14/2025 04:00 PM Eastern

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

Gyre Therapeutics stock logo

Gyre Therapeutics NASDAQ:GYRE

$10.39 -1.11 (-9.65%)
As of 05/14/2025 04:00 PM Eastern

Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.

Phibro Animal Health stock logo

Phibro Animal Health NASDAQ:PAHC

$23.36 -1.24 (-5.04%)
As of 05/14/2025 04:00 PM Eastern

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

Wave Life Sciences stock logo

Wave Life Sciences NASDAQ:WVE

$6.35 -0.04 (-0.63%)
As of 05/14/2025 04:00 PM Eastern

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.